Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Argus Health
Accenture
Federal Trade Commission
Covington
McKesson
Deloitte
Fish and Richardson
Citi
QuintilesIMS

Generated: January 18, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,299,052

« Back to Dashboard

Which drugs does patent 8,299,052 protect, and when does it expire?

Patent 8,299,052 protects MOXATAG and is included in one NDA.

This patent has eleven patent family members in six countries.
Summary for Patent: 8,299,052
Title:Pharmaceutical compositions and methods for improved bacterial eradication
Abstract: A process for treating a bacterial infection with an antibiotic, comprising: administering to a patient with a bacterial infection a product that includes a modified release dosage form containing an antibiotic, said product being administered once-a-day in a dosage and for a number of days that provides a Total T>MIC sufficient to achieve at least the minimum amount of bacterial eradication for treatment of said bacterial infection.
Inventor(s): Flanner; Henry H. (Montgomery Village, MD), Guttendorf; Robert (Gaithersburg, MD), Treacy; Donald (Woodbine, MD), Clausen; Susan P. (Ijamsville, MD), Burnside; Beth A. (Bethesda, MD)
Assignee: Shionogi Inc. (Florham Park, NJ)
Application Number:11/800,574
Patent Claim Types:
see list of patent claims
Use; Dosage form; Process;

Drugs Protected by US Patent 8,299,052

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Vernalis R And D Ltd MOXATAG amoxicillin TABLET, EXTENDED RELEASE;ORAL 050813-001 Jan 23, 2008 RX Yes Yes ➤ Subscribe ➤ Subscribe USE OF ONCE-A-DAY AMOXICILLIN PRODUCT TO TREAT TONSILLITIS AND/OR PHARYNGITIS SECONDARY TO STREPTOCOCCUS PYOGENES ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,299,052

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,357,394 Compositions and methods for improved efficacy of penicillin-type antibiotics ➤ Subscribe
8,778,924 Modified release amoxicillin products ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,299,052

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
World Intellectual Property Organization (WIPO) 2007067770 ➤ Subscribe
Japan 5788142 ➤ Subscribe
Japan 2010511607 ➤ Subscribe
European Patent Office 1969134 ➤ Subscribe
European Patent Office 1968586 ➤ Subscribe
China 101563466 ➤ Subscribe
Canada 2635606 ➤ Subscribe
Canada 2635378 ➤ Subscribe
Australia 2006351475 ➤ Subscribe
Australia 2006321782 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Moodys
Federal Trade Commission
Healthtrust
Chubb
Citi
US Army
Fish and Richardson
Argus Health
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot